- Prof. Dr. Andreas Busch, Chairman, (Zug, CH)
- Dr. Christine Lemke, Vice-Chairman (Zürich, CH)
- Prof. Dr. Christa E. Müller, Uni Bonn, Pharmazentrum und BIGS
- Prof. Dr. Larry Marnett, Vanderbilt Nashville, USA
- Dr. Jens v. Kries (FMP Berlin)
- Dr. Gerhard Müller (Spirochem, Basel, CH)
Major decisions of the SAB-boardmeetings 2018, 2020 and 2022:
- Reshaping Focus on Oncology as both “Time to Realisation” and “Potential for Personalized Therapy” are best for this Indication. In addition, Oncology is the key driver for innovation with newly registered drugs over the last years.
- Expand from Virtual Screen to Wetlab-Screen at FMP-Berlin
- Link and transfer to NCT-SW as clinical trial platform
